Climb Bio (CLYM) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio (CLYM) has outperformed Sagimet Biosciences Series A (SGMT) over the past year, gaining 549.1% versus a gain of 21.0%. Sagimet Biosciences Series A is the larger company by market cap ($629.7 million vs $615.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | SGMT |
|---|---|---|
| Share price | $10.71 | $8.88 |
| Market cap | $615.14M | $629.67M |
| 1-day change | +0.28% | +1.37% |
| YTD return | +167.75% | +50.00% |
| 1-year return | +549.09% | +20.98% |
| 5-year return | -33.64% | — |
| EPS (TTM) | $-0.82 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $11.45 |
| 52-week low | $1.64 | $4.50 |
| Distance from 52-week high | -41.57% | -22.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +157.42% | +214.30% |
| Average volume | 1.39M | 1.24M |
| Shares outstanding | 57.44M | 70.34M |
| Employees | 28 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed SGMT by 528.1 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Healthcare · Biotechnology · 28 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Healthcare · Biotechnology · 16 employees
CLYM vs SGMT FAQ
Which is bigger, Climb Bio or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $629.67M compared with $615.14M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or SGMT?
CLYM returned +549.09% over the past 12 months, compared with +20.98% for SGMT (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.